|
|
||||
|
IPO + Biotech = Uncertainty
The Scientist 2004, 18(15):12
|
||||
|
|
||||
|
After a long famine, and buoyed by the stock market's overall health over the past 18 months, investors are once again feasting on initial public offerings (IPOs). Prominent among them are biotech firms. The news is good for the cash-starved biotech companies, since they finally have a place to raise money. But the news is not as good for IPO investors, who are getting uncertain returns in the post-IPO aftermarket.
|
|
|||||||||
|
|||||||||
|
